CRISPR Therapeutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	371.21	1.2	914.96	0.72	289.59	3.12	41	5.16	0.25	0
Revenue Growth (YoY)	30885.48%	-99.87%	127154.94%	-99.75%	9169.85%	-92.38%	693.90%	1990.69%	-	-
Gross Profit	371.21	1.2	914.96	0.72	289.59	3.12	41	5.16	0.25	0
Selling, General & Admin	76.16	102.46	99.69	85.75	63.49	48.29	35.85	31.06	13.4	5.11
Research & Development	517.58	571.9	441.75	269.41	179.36	113.77	69.8	42.24	12.57	1.51
Operating Expenses	593.74	674.36	541.44	355.15	242.85	162.07	105.65	73.29	25.98	6.63
Operating Income	-222.54	-673.16	373.53	-354.44	46.74	-158.94	-64.65	-68.13	-25.73	-6.63
Interest Expense / Income	0	0	0	0	0	0	0	8.05	0.11	0
Other Expense / Income	-71.82	-22.66	-6	-6.38	-20.57	5.49	1.96	-53.49	-0.34	-0.3
Pretax Income	-150.72	-650.5	379.53	-348.06	67.31	-164.43	-66.61	-22.69	-25.5	-6.33
Income Tax	2.89	-0.33	1.87	0.81	0.45	0.55	1.75	0.48	0.01	-0.06
Net Income	-153.61	-650.18	377.66	-348.87	66.86	-164.98	-68.36	-23.18	-25.5	-6.26
Preferred Dividends	0	0	0	0	0	0	0	0	0	0.75
Net Income Common	-153.61	-650.18	377.66	-348.87	66.86	-164.98	-68.36	-23.18	-25.5	-7.01
Shares Outstanding (Basic)	79	78	76	66	54	48	40	12	5	4
Shares Outstanding (Diluted)	79	78	80	66	57	48	40	12	5	4
Shares Change	1.90%	-3.29%	21.90%	15.84%	18.70%	19.74%	226.80%	143.33%	41.50%	-
EPS (Basic)	-1.94	-8.36	4.97	-5.29	1.23	-3.44	-1.71	-1.89	-5.06	1.97
EPS (Diluted)	-1.94	-8.36	4.70	-5.29	1.17	-3.44	-1.71	-1.89	-5.06	1.97
Free Cash Flow	-269.85	-532.93	457.27	-256.72	49.99	-99.01	-77.91	-55.88	58.27	-4.79
Free Cash Flow Per Share	-3.41	-6.86	6.02	-3.89	0.92	-2.06	-1.95	-4.56	11.57	-1.35
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-59.95%	-56190.40%	40.82%	-49295.55%	16.14%	-5087.80%	-157.69%	-1319.33%	-10416.60%	-
Profit Margin	-41.38%	-54271.70%	41.28%	-48520.86%	23.09%	-5281.08%	-166.74%	-448.82%	-10325.10%	-
Free Cash Flow Margin	-72.69%	-44484.89%	49.98%	-35705.70%	17.26%	-3169.40%	-190.03%	-1082.03%	23592.71%	-
Effective Tax Rate	-	-	0.49%	-	0.67%	-	-	-	-	-
EBITDA	-130.89	-626.33	397.48	-338.87	72.03	-160.91	-63.58	-13.72	-25.26	-6.29
EBITDA Margin	-35.26%	-52281.14%	43.44%	-47131.02%	24.87%	-5150.74%	-155.09%	-265.65%	-10227.13%	-
Depreciation & Amortization	19.84	24.17	17.95	9.18	4.73	3.52	3.02	0.93	0.13	0.04
EBIT	-150.72	-650.5	379.53	-348.06	67.31	-164.43	-66.61	-14.64	-25.39	-6.33
EBIT Margin	-40.60%	-54298.83%	41.48%	-48408.34%	23.24%	-5263.38%	-162.47%	-283.56%	-10278.54%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).